Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Yisheng Completes Successful Phase I Test of Hepatitis B Vaccine

publication date: Nov 21, 2016
Yisheng Biopharma of Beijing completed a Phase I trial of its novel PIKA hepatitis B vaccine, which both treats and prevents the disease. The vaccine includes Yisheng's double-stranded RNA analog (PIKA) adjuvant that acts as a toll-like receptor 3 agonist. In 32 healthy volunteers, the vaccine was well tolerated and created immunogenicity in the subjects. Previously, the PIKA technology has been validated in several rabies vaccine trials, and earlier this month, Yisheng announced it would add the technology to an Scripps Research Institute AIDS vaccine for clinical testing. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital